Under this agreement, our Israeli subsidiary pays royalties to Ramot ranging between three percent (3%) and five percent (5%) of all net sales derived from the licensed intellectual property
During the reporting period, the Company settled outstanding accounts payable to a supplier in the amount of $ 450 through the issuance of 281,250 shares of common stock.
Brainstorm Cell Therapeutics Inc. Customers
No clients on recordNo downstream customers found in our database for Brainstorm Cell Therapeutics Inc..
Brainstorm Cell Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BCLI-DEBT
Debt stack $1.2M
90%
Market cache reports total debt of $1.2M.
BCLI-DEBT-8102
Warrants outstanding: 250000
90%
xbrl warrant detail from xbrl 2025-12-31.
BCLI-DEBT-8103
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-12-31.
Brainstorm Cell Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Brainstorm Cell Therapeutics Inc..
Brainstorm Cell Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
BCLI-OWNER-OSAIC-HOLDINGS-INC
OSAIC HOLDINGS, INC.
90%
13F overlay lists OSAIC HOLDINGS, INC. as top holder; 5 tracked holders.
Brainstorm Cell Therapeutics Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
Brainstorm Cell Therapeutics Inc. Supply Chain Intel